Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 15, 2010

View Archived Issues

Alnylam provides key goals for next 18 months

Pharmasset provides new data on HCV candidate PSI-7851

ERalphaS118-P a potential biomarker for breast cancer response to tamoxifen

Novo Nordisk commences phase I trial with long-acting oral GLP-1 analogue

Sciele Pharma changes company name to Shionogi Pharma

Isis adds new drug to treat hypertriglyceridemia to development pipeline

Amicus Therapeutics presents development progress with Amigal

InterMune provides update on 2010 development program for RG-7227

Sorrento enters antibody alliance for MRSA infections

Idenix reports updated information on three of its HCV programs

AnaptysBio and Roche sign agreement for development of novel antibody therapeutics

Pharmaxis acquires Topigen

Shionogi receives marketing approval for peramivir in Japan

Genaera to sell remaining proprietary assets

Spectrum completes enrollment in second phase III pivotal apaziquone trial

Eisai submits application for approval of additional indication of Tambocor in Japan

Genfit reports results from phase I safety study of GFT-505/simvastatin combination

siRNA-nanosome formulations inhibit HCV RNA replication in interferon-resistant replicon cells

Activated protein C analogues slow progression in ALS model

Top2alpha proteasomal degradation can be inhibited to enhance cancer treatment

Novel sulfonylureas in development for diabetes therapy at Concert Pharmaceuticals

Bristol-Myers Squibb presents novel hepatitis C virus inhibitors

Yakult Honsha discovers novel Plk-1 inhibitors as oncolytics

Novel peptides for the diagnosis of invasive brain cancer described by U.S. scientists

Actelion Pharmaceuticals discloses novel antibacterials

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 13, 2026.
Alzheimer’s, beyond the brain
BioWorld
Researchers at Daping Hospital in China have reported that liver-targeted delivery of the APOE3-Christchurch (APOE3Ch) variant, a rare protective form of...
News in brief
BioWorld Asia
BioWorld Asia briefs for May 12, 2026
First cruise ship hantavirus genome points to zoonotic spillover
BioWorld
The initial appraisal of the first complete genome sequence of a hantavirus isolated from a patient in Switzerland who was a passenger on the cruise ship MV...
Advancing the 'best of both' – BMS, Hengrui enter $15.2B deal
BioWorld
In a deal potentially worth up to $15.2 billion, Jiangsu Hengrui Pharmaceuticals Co. Ltd. is joining efforts with Bristol Myers Squibb Co. to advance 13 early...